Ellen Gielen and Gertie Lintjens jointly head CMS‘ practice, which is known for advising on M&A, contentious reimbursement matters, and pricing negotiations. The 'very knowledgeable' Gielen has extensive experience in handling regulatory cases, often involving pharmaceutical and medical device issues, while Lintjens is well versed in handling R&D projects and early access matters involving pharma products. Judith Kok has a solid track record in assisting with biocides matters and distribution issues. Murat Duman joined the group in January 2024.
Legal 500 redaktioneller Kommentar
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
‘One of the most broad life sciences teams in the Netherlands covering all aspects of life sciences.’
‘Ellen Gielen has seen it all and thus has both the professional knowledge to help clients achieve their goals as well as the gravitas to guide you there.’
‘Ellen Gielen is great and very knowledgeable. I also enjoy working with Judith Kok.’
Kernmandanten
- Amgen
- Boston Scientific
- Brocacef
- Carl Zeiss
- Eli Lilly
- Essity
- Johnson & Johnson
- LEO Pharma
- Mölnlycke Health Care
- Netherlands Cancer Institute
Highlight-Mandate
- Represented Eli Lilly in litigation concerning reimbursement of its breast cancer treatment Verzenios.
- Advised Carl Zeiss Meditec AG on its agreement to acquire DORC from investment firm Eurazeo SE for EUR 985 million.
- Advising Boston Scientific on the development of a logistics center in the Netherlands.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Partner*innen der nächsten Generation
Juniorpartner*innen, die im Markt von Mandanten und Wettbewerbern anerkannt werden und in einigen Mandaten eine Schlüsselrolle einnehmen.
Praxisleitung
Ellen Gielen; Gertie Lintjens
Weitere Kernanwält*innen
Judith Kok; Renate Bik; Murat Duman